PubMed · 2016 · 162 citations · 22 references
MedicineOncologyRadiologyDiagnostic ImagingDiagnostic RadiologyNeuro-oncologyBrain ImagingBrain MetastasesBrain MetastasisBrain TumorsCentral Nervous System TumorsMetastatic Brain Tumors18F-fluorodeoxyglucose Positron Emission TomographyBrain Tumor DiagnosisFluorine-18 Fluorodeoxyglucose Positron Emission TomographyHistopathology Of Brain TumorsLesion ClassificationPrimary Brain NeoplasmsPrimary Tumor AssessmentPrimary Tumor Classification
Primary intracranial tumors of the brain structures, including meninges, are rare with an overall five-year survival rate of 33.4%; they are collectively called primary brain tumors. Proven risk factors for these tumors include certain genetic syndromes and exposure to high-dose ionizing radiation. Primary brain tumors are classified by histopathologic criteria and immunohistochemical data. The most common symptoms of these tumors are headache and seizures. Diagnosis of a suspected brain tumor is dependent on appropriate brain imaging and histopathology. The imaging modality of choice is gadolinium-enhanced magnetic resonance imaging. There is no specific pathognomonic feature on imaging that differentiates between primary brain tumors and metastatic or nonneoplastic disease. In cases of suspected or pathologically proven metastatic disease, chest and abdomen computed tomography may be helpful, although determining the site of the primary tumor is often difficult, especially if there are no clinical clues from the history and physical examination. Using fluorodeoxyglucose positron emission tomography to search for a primary lesion is not recommended because of low specificity for differentiating a neoplasm from benign or inflammatory lesions. Treatment decisions are individualized by a multidisciplinary team based on tumor type and location, malignancy potential, and the patient's age and physical condition. Treatment often includes a combination of surgery, radiotherapy, and chemotherapy. After craniotomy, patients should be followed closely for complications, including deep venous thrombosis, pulmonary embolism, intracranial bleeding, wound infection, systemic infection, seizure, depression, worsening neurologic status, and adverse drug reaction. Hospice and palliative care should be offered when appropriate throughout treatment.
22
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas
Michael Walker, Eben Alexander, William E. Hunt et al. · Journal of neurosurgery · 1978 · 1.7K citations
Gary H. Lyman, Kari Bohlke, Alok A. Khorana et al. · Journal of Clinical Oncology · 2015 · 1.4K citations · Full text
Medicine, Hematology, Surgery +17